NasdaqCM - Nasdaq Real Time Price USD

Shuttle Pharmaceuticals Holdings, Inc. (SHPH)

Compare
0.8700
+0.0010
+(0.12%)
At close: January 10 at 4:00:00 PM EST
0.8211
-0.05
(-5.62%)
After hours: 7:47:39 PM EST
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for SHPH

Recent News: SHPH

View More
Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
GlobeNewswire 3 days ago
Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program

Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program
GlobeNewswire 22 days ago
Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient

Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient
GlobeNewswire last month
Shuttle Pharma Provides Third Quarter 2024 Corporate Update

Shuttle Pharma Provides Third Quarter 2024 Corporate Update
GlobeNewswire last month
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
GlobeNewswire 2 months ago
Shuttle Pharma Pays Off Senior Secured Convertible Note

Shuttle Pharma Pays Off Senior Secured Convertible Note
GlobeNewswire 2 months ago
Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
GlobeNewswire 2 months ago
Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
GlobeNewswire 2 months ago
Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024

Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024
GlobeNewswire 2 months ago
Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
GlobeNewswire 3 months ago
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing

Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
ACCESSWIRE 3 months ago
View More

Related Tickers

ETST Earth Science Tech, Inc.
0.1252
+0.08%
 
CPHI China Pharma Holdings, Inc.
0.2199
+4.17%
 
AKAN Akanda Corp.
1.5600
-3.11%
 
PTPI Petros Pharmaceuticals, Inc.
0.3761
+3.32%
 
SXTC China SXT Pharmaceuticals, Inc.
0.4693
-1.82%
 
BGXX Bright Green Corporation
0.0683
-5.21%
 
CLSH CLS Holdings USA, Inc.
0.0316
+5.33%
 
CPIX Cumberland Pharmaceuticals Inc.
2.3300
+4.48%
 
IXHL Incannex Healthcare Inc.
1.8500
-0.54%
 
IMCC IM Cannabis Corp.
2.4400
-2.01%